Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Obinutuzumab in Fit Patients With Previously Untreated CLL
NCT04447768Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2020
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, obinutuzumab in chronic lymphocytic leukemia (CLL), sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2020; status: active, not recruiting.
02
Drugs
venetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04447768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04447768.